Segmented Iron Supplement Container for Anemia Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing iron supplementation methods, such as iron succinylated protein complexes, often result in low absorption capacity and severe gastrointestinal side effects, making them unsuitable for long-term therapy, especially in conditions like iron deficiency anemia.
Innovation Solution
A pharmaceutical composition comprising a ferric complex with N-acetyl-L-aspartic casein and calcium folinate pentahydrate, where the two active ingredients are stored separately and mixed immediately before use, utilizing a specialized container design to prevent bacterial contamination and ensure effective absorption by avoiding high molecular weight iron hydroxide formation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If iron supplementation is provided using conventional methods (e.g., iron succinylated protein complexes), then iron delivery is achieved, but absorption capacity is low and gastrointestinal side effects are severe
Solution Approach 1:
The iron supplement is divided into two separate components stored in different compartments: ferric complex with N-acetyl-L-aspartic casein (solid form) and calcium folinate pentahydrate (liquid form). This segmentation allows each component to be optimized independently, preventing the formation of high molecular weight iron hydroxides that cause poor absorption and gastrointestinal side effects, while enabling rapid iron release and improved bioavailability when mixed together
Solution Approach 2:
Calcium folinate pentahydrate acts as an intermediary substance that enhances iron absorption. When mixed with the ferric complex, it facilitates the release of bioavailable iron without forming problematic iron hydroxides, thereby improving absorption capacity and reducing gastrointestinal side effects through this mediating mechanism
2Duration of action of stationary object
If iron supplementation is provided using conventional methods, then iron delivery is achieved, but tolerability is poor making long-term therapy unsuitable
Solution Approach 1:
By segmenting the iron supplement into two separate components (ferric complex and calcium folinate) stored in different compartments, the formulation avoids the formation of high molecular weight iron hydroxides that cause adverse effects. This segmentation enables long-term therapy by significantly improving tolerability and reducing gastrointestinal side effects
Solution Approach 2:
The invention changes the chemical parameters of iron supplementation by using ferric complex with N-acetyl-L-aspartic casein instead of conventional iron salts, and by controlling the pH environment through calcium folinate. This parameter change transforms the iron delivery system to produce rapid iron release with minimal adverse effects, making it suitable for long-term therapy
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition provides rapid and sustained bioavailable iron levels with reduced side effects, enhanced tolerability, and improved absorption, particularly beneficial for long-term therapy and conditions like anemia, especially during pregnancy and lactation.
Implementation Method 1
The ferric complex with N-acetyl-L-aspartic casein (ICA) is an amorphous, slightly hygroscopic powder that is insoluble in all organic solvents and is soluble only in alkaline aqueous solutions at pH 8. ICA complex is an Iron (III) complex with N-acetyl-L-aspartic derivative of casein. ICA complex acts as an effective carrier for iron presenting a positive and well-tolerable safety profile. The main feature of ICA complex is that it restricts the interaction of iron ions with the gastric mucosa, thus preventing the formation of high molecular weight iron hydroxides, which are poorly absorbed.
Implementation Method 2
Then, ICA complex is hydrolyzed by pancreatic proteases at the alkaline pH of the duodenum and iron (III) in bioavailable form is absorbed in the small intestine.
Implementation Method 3
Calcium folinate is easily soluble in aqueous solutions, can be absorbed by the proximal part of the small intestine and is rapidly distributed to the tissues, where it is converted into biologically active folinic acid.
Data Source
AI summary
The present invention relates to pharmaceutical composition in the form of a single-dose oral solution comprising the ferric complex with N-acetyl-L-aspartic casein and calcium folinate pentahydrate as the active ingredients. The ferric complex with N-acetyl-L-aspartic casein is standardized in trivalent iron and complexed N-Acetyl-L-aspartic acid and is stored in a cylindrical bottle in liquid form. Calcium folinate pentahydrate is stored in solid form in the closure storage cap and kept separated in a sealed manner from the solution which is stored in the bottle. The device bottle-closure storage cap allows the mixing of the two active ingredients just before their administration as a single dose oral solution. The resulting pharmaceutical composition helps to deal with both chronic anemia and anemia during pregnancy and lactation.